This site is intended only for Australian Healthcare Professionals

Search

Menu

Close

Sign In or RegisterLog OutOur medicinesTherapy areasExplore contentExplore contentEventsVideosMaterialsLet’s connectLet's ConnectContact usAsk a questionPfizer Medical InformationStay connectedSuggest a topicPharmacy HubKnowledge Hub

Menu

Close

IndicationsTherapeutic indicationsRheumatoid arthritisJuvenile idiopathic arthritisPsoriatic arthritisAxial spondylarthritisPlaque psoriasisPaediatric plaque psoriasisAbout ENBRELMechanism of actionHalf-lifeAdmin & storageAdministration & storageAdministrationAuto-InjectorPre-filled SyringeVialStorageInstructions for useResources & supportResources & supportPatient ResourceseXtend Access ProgramPfizerFlex™ Patient Support ProgramExplore contentEventsMaterialsVideosOrder starter packs
Rheumatoid arthritis
RA icon

Therapeutic indication

ENBREL is indicated for the treatment of:

  • Active, adult rheumatoid arthritis (RA) in patients who have had inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). ENBREL can be used in combination with methotrexate.1
  • Severe, active rheumatoid arthritis in adults to slow progression of disease-associated structural damage in patients at high risk of erosive disease.1
Dosing icon

Dosing
  • The recommended dose of ENBREL® is 50 mg per week, given as a subcutaneous injection, EITHER once weekly as a single 50 mg injection OR twice weekly as two separate 25 mg injections given 3-4 days apart.1
  • Elderly RA patients (age ≥ 65 years) show similar safety, efficacy and pharmacokinetic profiles compared to younger adult patients treated with ENBREL. Dose adjustment is not needed for the elderly. However, as with other medicinal products, greater sensitivity in some older patients cannot be ruled out.1
Explore More Product Information

Before prescribing, please review full Product Information (PI).

 View PILoading PBS

ENBREL is listed on the Pharmaceutical Benefits Scheme (PBS).

 View PBSLoading CMI

Download a copy of the ENBREL Consumer Medicine Information (CMI) for your patient.

 View CMILoading
ENBREL starter packs Available for eligible healthcare professionals.
  Request starter packs Loading
ENBREL access: eXtend An access program for patients requiring treatment with ENBREL for a registered indication.Visit eXtend Access Program Loading
Pfizer Knowledge Hub On-demand educational content delivered by experts at the forefront of rheumatology. Visit Knowledge HubLoading
Therapeutic indicationsCMI: Consumer Medicine Information; DMARD: disease-modifying anti-rheumatic drug; PBS: Pharmaceutical Benefits Scheme; PI: Product Information; RA: Rheumatoid arthritis.
Reference:ENBREL Product Information.

Before prescribing, please review Product Information available here​

PBS Information: Authority required. Refer to PBS Schedule for full information.

Enbrel is a ®Registered Trademark.​

PP-ENB-AUS-1152. ENB-003001-00. 04/25.
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about Pfizer medicines and vaccines.

Sign inRegisterAccountSign Out

The site is intended for Australian healthcare professionals.

 

©2023 Pfizer Australia Pty Ltd. Sydney, Australia. All rights reserved.

 

 

PP-UNP-AUS-0551 12/23.

You are now leaving Pfizer
You are leaving PfizerPro.
You may be directed to a third-party website.
Please note third-party websites are not controlled by Pfizer or subject to our privacy policy.
 
PP-UNP-AUS-0551 12/23.